10.1002/ejoc.201901623
European Journal of Organic Chemistry
FULL PAPER
placed in the freezer overnight. The crystals were washed with pentane (5
x 1 mL) and dried in vacuo to give complex Ic as a colourless solid (22.0
mg, 61%).
CH3OCCH2), 1.85-1.76 (m, 3H, CCH2CH2 and CH2CHCH2 and
CHCH2CH2), 1.49 (d, 1H, J = 13.6 Hz, CH3OCCH2), 1.42 (dd, 37H, J =
15.5/11.3 Hz, t-Bu and CCH2CH2), 1.26-1.22 (m, 1H, CHCH2CH2), 0.950
(s, 3H, CH3), 0.946 (s, 3H, CH3), 0.88 (s, 3H, CH3); 13C NMR (150 MHz,
CDCl3): δ ppm 149.1 (d, J = 13.8 Hz, CAr), 133.8 (br s, CHAr), 133.4 (d, J =
7.5 Hz, CHAr), 132.1 (t, J = 11.8 Hz, AuCC), 131.2 (br s, CHAr), 129.4 (d, J
= 5.4 Hz, CHAr), 129.3 (CHAr), 129.0 (CHAr), 127.8 (CHAr), 127.5 (d, J = 7.1
Hz, CHAr), 124.6 (d, J = 44.7 Hz, PCAr), 117.0 (t, J = 68.7 Hz, AuC), 85.0
(OC), 55.1 (CCH3), 50.1 (OCH3), 48.6 (C(CH3)2), 45.4 (CH2CHCH2), 44.0
(CH3OCCH2), 38.4 (dd, 24.4/24.4 Hz, PC(CH3)3), 32.8 (CCH2CH2), 31.0
(dd, J = 20.0/6.8 Hz, PC(CH3)3), 27.1 (C), 21.3 (CH3), 20.8 (CH3), 11.7
(CH3); 31P NMR (162 MHz, CDCl3): δ ppm 61.95; IR (neat, cm-1) 2950,
2900, 1471, 1391, 1369, 1170, 1084, 755, 702, 655, 526, 475; HRMS (ESI)
calcd for C52H71OP2Au2 [M]+ 1167.4311, found 1167.4329.
Method
A
(0.5 eq alkyne):
(Acetonitrile)[(2-biphenyl)di-tert-
butylphosphine]gold(I) hexafluoroantimonate (20.0 mg, 1 eq) and DIPEA
(5 µL, 1.1 eq) were mixed in DCM (1.0 mL), then alkyne 1c (3.8 mg, 1.0
eq) in DCM (1.0 mL) was added. was added. After stirring for 5 min, 2 mL
DCM was added and the mixture was washed with water (5 x 2 mL), the
organic phase dried over Na2SO4, filtered and evaporated. The resulting
powder was dissolved in ca. 0.25 mL DCM and 4 mL pentane added
carefully and placed in the freezer overnight. The crystals were washed
with pentane (5 x 1 mL) and dried in vacuo to give complex Ic as a
colourless solid (13.8 mg, 78%).
1H NMR (400 MHz, CDCl3): δ ppm 7.88-7.84 (m, 2H, CHAr, ligand), 7.53-7.50
(m, 4H, CHAr, ligand), 7.38 (d, J = 8.3 Hz, CHAr, acetylide), 7.28-7.19 (m, 8H,
CHAr, ligand), 7.08-7.05 (m, 4H, CHAr, ligand), 6.81-6.77 (m, 2H, CHAr, acetylide,
ortho to OMe), 3.86 (s, 3H, OCH3), 2.45 (s, 3H, CH3), 1.39 (d, J = 15.6 Hz, t-
Bu); 13C NMR (150 MHz, CDCl3): δ ppm 161.5 (COCH3), 149.3 (d, J = 13.9
Hz, CAr, ligand), 144.5 (CH3CAr, acetylide), 142.3 (d, J = 7.4 Hz, CAr, ligand), 136.0
(CHAr, acetylide, meta to OMe), 133.9 (br s, CHAr, ligand), 133.3 (d, J = 8.0 Hz, CHAr,
ligand), 131.1 (CHAr, ligand), 129.3 (CHAr, ligand), 129.0 (CHAr, ligand), 128.0 (CHAr,
ligand), 127.4 (d, J = 7.5 Hz, CHAr, ligand), 125.2 (d, C, J = 44.3 Hz, CAr, ligand),
123.7 (t, J = 69.3 Hz, AuC), 123.5 (t, J = 10.8 Hz, AuCC), 115.3 (CHAr,
acetylide, ortho to OMe), 112.1 (CAr, acetylide, ortho to OMe), 111.8 (CHAr, acetylide), 55.5
(OCH3), 38.1 (d, J = 24.7 Hz, PC), 31.0 (d, J = 7.5 Hz, PCC), 21.4 (CH3);
31P NMR (162 MHz, CDCl3): δ ppm 62.31; IR (neat, cm-1) 2954, 2898, 2865,
2018, 1603, 1561, 1466, 1366, 1295, 1247, 754, 733, 699, 656, 525, 498;
HRMS (ES+) calcd for C50H63OP2Au2 [M]+ 1135.3685, found 1135.3696.
General procedure for synthesis of Complexes V
A
solution
of
(R)-(6,6'-dimethoxy-[1,1'-biphenyl]-2,2'-
diyl)bis(diphenylphosphine) (9.9 mg, 0.017 mmol) in DCM (1 mL) was
added to chloro(dimethylsulfide)gold (10 mg, 0.034 mmol) in DCM (1 mL).
The resulting solution was stirred for 5-10 min then silver
hexafluoroantimonate (11.7 mg, 0,034 mmol) was added and the mixture
filtered. A mixture of N-ethyl-N-isopropylpropan-2-amine (5 µl, 0.029
mmol) and alkyne 1a, 1b or 1g (0.017 mmol) in a small amount of DCM
was added. The mixture was stirred for 5-10 min then washed with water
5x1mL, dried over Na2SO4, filtered and evaporated. The residue was
washed with pentane (3 x 1 mL) to give the required gold complex. The
complexes tended to retain a small amount of pentane and where
necessary, the yield was calculated from 1H NMR.
Complex Id (diOMe)
Complex Va (BIPHEP-CF3)
Method
A:
(Acetonitrile)[(2-biphenyl)di-tert-butylphosphine]gold(I)
Complex Va was synthesised according to the general procedure above
using alkyne 1a (2.9 mg, 1.0 eq) to give the desired complex as a yellow
solid (20.5 mg, 87%). 1H NMR (600 MHz, CD2Cl2): δ ppm 7.75 (d, 2H, CHAr,
acetylide), 7.60-7.56 (m, 4H, 2xCHAr, ligand, Ph, 2xCHAr, acetylide), 7.54-7.51 (m,
4H, CHAr, ligand, Ph), 7.37-7.27 (m, 6H, CHAr, ligand, Ph), 7.29 (dt, 2H, J = 8.1/2.1
Hz, CHAr, ligand), 7.20-7.17 (m, 4H, CHAr, ligand, Ph), 7.13 (dd, 4H, J = 13.3/7.5
Hz, CHAr, ligand, Ph), 6.93 (dd, 2H, J = 9.8/8.1 Hz, CHAr, ligand), 6.61 (d, 2H, J
= 8.4 Hz, CHAr, ligand), 2.91 (s, 6H, OCH3); 13C NMR (150 MHz, CD2Cl2): δ
ppm 159.4-159.3 (m, 2C, COCH3, ligand), 136.1-136.0 (m, 4C, CHAr, ligand, Ph),
134.7-134.6 (m, 4C, CHAr, ligand, Ph), 133.4 (s, (m, 2C, CHAr, acetylide), 133.3
(m, 2C, CHAr, ligand, Ph), 132.5 (m, 2C, CHAr, ligand, Ph), 131.0-130.9 (m, 2C,
CHAr, ligand), 130.3 (dm, 2C, J = 62.3 Hz, PCAr, ligand), 129.75-129.68 (m, 4C,
CHAr, ligand, Ph), 129.3-129.2 (m, 4C, CHAr, ligand, Ph), 128.3 (d, 2C, J = 61.4
Hz, PCAr, Ph), 128.3-128.2 (m, 2C, PCCAr, ligand), 126.7 (q, 1C, J = 3.3 Hz,
CHCCF3), 126.2 (d, 2C, J = 63.7 Hz, PCAr, Ph),125.2 (br s, 2C, PCCHAr,
ligand), 123.9 (q, 1C, J = 272.8 Hz, CF3), 123.8 (1C, CAr, acetylide), 117.6 (only
HMBC, AuCC), 114.7 (s, 2C, CHAr, ligand), missing, AuC and CCF3; 19F NMR
(376 MHz, CD2Cl2): δ ppm −63.34; 31P NMR (162 MHz, CDCl3): δ ppm
29.29; IR (neat, cm-1) 3056, 2936, 2837, 1567, 1460, 1435, 1156, 1123,
1097, 1064, 1043, 845, 743, 691, 654, 500; HRMS (ES+) calcd for
C47H36O2F3P2Au2 [M+] 1145.1474, found 1145.1473.
hexafluoroantimonate (40.5 mg, 1 eq) and DIPEA (10 µL, 1.1 eq) were
mixed in DCM (1 mL), then alkyne 1d (4.2 mg, 0.5 eq) in DCM (1 mL) was
added. After stirring for 5 min, 2 mL DCM was added and the mixture was
washed with water (5 x 2 mL), the organic phase dried over Na2SO4,
filtered and evaporated. The resulting powder was dissolved in ca. 0.25
mL DCM and 4 mL pentane added carefully and placed in the freezer
overnight. The crystals were washed with pentane (5 x 1 mL) and dried in
vacuo to give complex Id as a colourless powder (32.5 mg, 45%).
1H NMR (600 MHz, CDCl3): δ ppm 7.87-7.85 (m, 2H, CHAr, ligand), 7.54-7.51
(m, 4H, CHAr, ligand), 7.36-7.30 (m, 6H, CHAr, ligand), 7.24-7.21 (m, 2H, CHAr,
ligand), 7.11 (dd, 1H, J = 8.3/1.9 Hz, CHAr, acetylide), 7.09-7.07 (m, 4H, CHAr,
ligand), 6.94 (dd, 1H, J = 8.4/1.5 Hz, CHAr, acetylide), 6.89 (d, 1H, J = 1.8 Hz,
CHAr, acetylide), 3.95 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 1.39 (d, 36H, J =
15.7 Hz, t-Bu); 13C NMR (150 MHz, CDCl3): δ ppm 151.3 (CAr, acetylide),
149.2 (d, J = 14.0 Hz, CAr, ligand), 148.6 (CAr, acetylide), 142.6 (d, J = 6.8 Hz,
CAr, ligand), 133.9 (br s, CHAr, ligand), 133.3 (d, J = 7.7 Hz, CHAr, ligand), 131.1
(br s, CHAr, ligand), 129.3 CHAr, ligand), 129.0 CHAr, ligand), 128.0 (CHAr, ligand),
127.5 (d, J = 7.5 Hz, CHAr, ligand), 127.3 (CHAr, acetylide), 125.2 (d, J = 44.8 Hz,
PCAr), 124.6 (t, J = 68.5 Hz, AuC), 118.2 (t, J = 11.4 Hz, AuCC), 115.3
(CHAr, acetylide), 112.5 (CAr, acetylide), 111.2 (CHAr, acetylide), 56.1 (2xOCH3), 38.0
(d, J = 22.7, C(CH3)3), 31.0 (d, J = 7.0 Hz, PC(CH3)3); 31P NMR (162 MHz,
CDCl3): δ ppm 62.35; IR (neat, cm-1) 2947, 2899, 2865, 2017, 1592, 1508,
1463, 1263, 1136,1023, 753, 699, 655, 525; HRMS (ESI) calcd for
C50H63O2P2Au2 [M]+ 1151.3634, found 1151.3649.
Complex Vb (BIPHEP-OMe)
Complex Vb was synthesised according to the general procedure above
using alkyne 1b (2.3 mg, 1.0 eq) to give the desired complex as a yellow
1
solid (19.4 mg, 85%). H NMR (600 MHz, CD2Cl2): δ ppm 7.58-7.52 (m,
Complex If (camphorOMe)
6H, CHAr, ligand), 7.40-7.37 (m, 2H, CHAr, acetylide), 7.34-7.31 (m, 4H, CHAr,
ligand), 7.29 (td, 2H, J = 8.3/2.5 Hz, CHAr, ligand), 7.28-7.23 (m, 2H, CHAr, ligand),
7.17-7.11 (m, 8H, CHAr, ligand), 7.03-7.01 (m, 2H, CHAr, acetylide), 6.97 (dd, 2H,
J = 10.5/7.9 Hz, CHAr, ligand), 6.57 (d, 2H, J = 8.5 Hz, CHAr, ligand), 3.95 (s,
3H, OCH3, acetylide), 2.87 (s, 6H, OCH3, ligand); 13C NMR (150 MHz, CD2Cl2):
δ ppm 163.3 (s, 1C, COCH3, acetylide), 159.3-159.2 (m, 2C, COCH3, ligand),
136.2-136.1 (m, 4C, CHAr, ligand, Ph), 135.8 (s, 2C, CHAr, acetylide), 134.8-134.7
(m, 4C, CHAr, ligand, Ph), 133.0 (s, 2C, CHAr, ligand, Ph), 132.1 (s, 2C, CHAr, ligand,
Ph), 130.81-130.74 (m, 2C, CHAr, ligand, Ar), 130.7 (dm, 2C, J = 63.1 Hz, PCAr),
129.44-129.37 (m, 4C, CHAr, ligand, Ph), 129.07-128.99 (m, 4C, CHAr, ligand, Ph),
128.4 (dm, 2C, J = 61.5 Hz, PCPh), 128.2-128.1 (m, 2C, PCC), 126.3 (dm,
2C, J = 63.2 Hz, PCPh), 125.2 (br s, 2C, CHAr, ligand, Ar), 119.5 (t, J = 72.2
Method
A:
(Acetonitrile)[(2-biphenyl)di-tert-butylphosphine]gold(I)
hexafluoroantimonate (21.2 mg, 1 eq) and DIPEA (10 µL, 2.1 eq) were
mixed in DCM (0.5 mL), then alkyne 1f (5.0 mg, 0.9 eq) in DCM (0.5 mL)
added. After 10 min stirring, the mixture was washed with water (5 x 1 mL),
the organic phase dried over Na2SO4, filtered and precipitated with
pentane. The solvents were evaporated and the resulting powder was
washed with pentane and dried in vacuo to give complex If as a colourless
powder (15.5 mg, 40%).
1H NMR (400 MHz, CDCl3): δ ppm 7.90-7.86 (m, 2H, CHAr, ligand), 7.54-7.52
(m, 4H, CHAr, ligand), 7.35-7.26 (m, 6H, CHAr, ligand), 7.22-7.18 (m, 2H, CHAr,
ligand), 7.13-7.08 (m, 4H, CHAr, ligand), 3.23 (s, OCH3), 2.37-2.32 (m, 1H,
9
This article is protected by copyright. All rights reserved.